Trials that use: Intention-to-treat analysis
New to this method? Read the tutorial →
228 results
- COMPASSIndependent statistical analysis of the COMPASS phase 3 trial of rivaroxaban-based antithrombotic treatment in coronary or peripheral artery disease, including trial design, time-to-event endpoints, hazard ratios, safety outcomes, statistical methods, and interpretation.
- CONTACT-01Independent statistical analysis of CONTACT-01, a randomized phase 3 trial of atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.
- CONTACT-03Independent statistical analysis of CONTACT-03, a randomized phase 3 trial of atezolizumab plus cabozantinib versus cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment.
- COSMIC-312Complete statistical analysis of COSMIC-312, the randomized phase 3 trial of cabozantinib plus atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma, including its time-to-event endpoints, hazard ratios, confidence intervals, p-values, and…
- COSMIC-313Independent statistical analysis of COSMIC-313, a randomized phase 3 trial of cabozantinib with nivolumab and ipilimumab versus placebo with nivolumab and ipilimumab in previously untreated advanced or metastatic renal cell carcinoma.
- COSSIndependent statistical analysis of the COSS phase 3 trial of extracranial-intracranial bypass surgery versus best medical therapy for symptomatic carotid occlusion, including its primary endpoint, secondary analyses, statistical methods, and interpretation.
- COU-AA-301Independent statistical analysis of COU-AA-301, a randomized phase 3 trial of abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, covering overall survival, progression, PSA response, trial design, and statistical…
- CREDENCEComplete statistical analysis of CREDENCE, the randomized phase 3 trial evaluating canagliflozin versus placebo for renal and cardiovascular outcomes in participants with type 2 diabetes and diabetic nephropathy.
- CRYSTALIndependent statistical analysis of the CRYSTAL phase 3 trial of cetuximab plus FOLFIRI versus FOLFIRI alone in EGFR-expressing metastatic colorectal cancer, including progression-free survival, overall survival, response, statistical methods, and interpretation.
- CRYSTAL-AFIndependent statistical analysis of CRYSTAL-AF, evaluating continuous cardiac monitoring with an insertable cardiac monitor for atrial fibrillation detection after cryptogenic stroke or transient ischemic attack.
- DAPA-CKDIndependent statistical analysis of the randomized phase 3 DAPA-CKD trial evaluating dapagliflozin versus placebo for renal and cardiovascular outcomes in patients with chronic kidney disease.
- DAPA-MIIndependent statistical analysis of the DAPA-MI phase 3 trial of dapagliflozin versus placebo after acute myocardial infarction, including its hierarchical primary composite endpoint, win-ratio methodology, trial design, interpretation, and safety.
- DELIVERIndependent statistical analysis of the DELIVER phase 3 trial of dapagliflozin in heart failure with preserved ejection fraction, including its dual primary time-to-event endpoints, Cox models, recurrent-event analysis, KCCQ analysis, safety, and…
- DESTINY-Breast02Complete statistical analysis of DESTINY-Breast02, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's/physician's choice in previously treated HER2-positive, unresectable and/or metastatic breast cancer.
- DESTINY-Breast04Independent statistical analysis of DESTINY-Breast04, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's choice for HER2-low breast cancer. Includes the reported progression-free survival analysis, trial design, statistical methodology, interpretation, and…
- DESTINY-Breast06Independent statistical analysis of DESTINY-Breast06 (NCT04494425), a randomized phase 3 trial comparing trastuzumab deruxtecan with investigator's choice chemotherapy in HER2-low, hormone receptor-positive, advanced or metastatic breast cancer.
- DISCOVERIndependent statistical analysis of the DISCOVER phase 3 trial evaluating F/TAF versus F/TDF for HIV-1 pre-exposure prophylaxis, including non-inferiority testing, rate-ratio analysis, BMD, renal biomarkers, and statistical methodology.
- DUO-EIndependent statistical analysis of the phase 3 DUO-E trial evaluating durvalumab with or without olaparib as maintenance therapy after first-line treatment of advanced and recurrent endometrial cancer.
- EINSTEIN-DVTIndependent statistical analysis of EINSTEIN-DVT, a randomized phase 3 trial of rivaroxaban versus enoxaparin followed by VKA in patients with venous thrombosis, including its non-inferiority analysis, Cox model, hazard ratio, confidence interval,…
- EINSTEIN-PEIndependent statistical analysis of EINSTEIN-PE, the randomized phase 3 trial of rivaroxaban versus enoxaparin followed by VKA in patients with acute symptomatic pulmonary embolism, including non-inferiority methodology, Cox analysis, hazard ratios, bleeding,…
- ELIXAIndependent statistical analysis of the ELIXA phase 3 trial of lixisenatide versus placebo in patients with acute coronary syndrome and type 2 diabetes, including its time-to-event endpoint, non-inferiority framework, hazard ratio, confidence…
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EMILIAIndependent statistical analysis of the phase 3 EMILIA trial of trastuzumab emtansine versus lapatinib plus capecitabine in HER2-positive locally advanced or metastatic breast cancer, including time-to-event methods, response analyses, safety, and interpretation.
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- ENESTndIndependent statistical analysis of ENESTnd (NCT00471497), a randomized phase 3 study comparing nilotinib with imatinib in adults with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
- ENGAGEIndependent statistical analysis of the ENGAGE phase 3 trial of aducanumab in early Alzheimer's disease, including randomized trial design, CDR-SB and cognitive endpoints, MMRM methodology, confidence intervals, p-values, and safety.
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- ENVISAGE-TAVI AFComplete statistical analysis of ENVISAGE-TAVI AF, the randomized phase 3 trial comparing an edoxaban-based regimen with a vitamin K antagonist-based regimen in patients with atrial fibrillation after catheter-based heart valve replacement.
- EORTC 18071Independent statistical analysis of EORTC 18071, a randomized phase 3 trial of ipilimumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, distant metastasis-free survival, overall survival, and…
- EUROMAXComplete statistical analysis of the EUROMAX phase 3 trial of bivalirudin versus standard-of-care heparins with optional GPI in acute coronary syndrome, including trial design, the primary binary endpoint, risk ratio, confidence interval,…
- EV-302Independent statistical analysis of EV-302, the randomized phase 3 trial of enfortumab vedotin plus pembrolizumab versus standard of care in untreated locally advanced or metastatic urothelial cancer.
- EVOKE-01Independent statistical analysis of EVOKE-01, a randomized phase 3 trial comparing sacituzumab govitecan with docetaxel in participants with advanced or metastatic non-small cell lung cancer, including overall survival, progression-free survival, response, patient-reported…
- EXSCELA detailed independent statistical analysis of EXSCEL, the phase 3 trial of exenatide once weekly versus placebo in patients with type 2 diabetes mellitus, including its randomized design, time-to-event endpoints, Cox models,…
- ExteNETIndependent statistical analysis of the phase 3 ExteNET trial of neratinib after adjuvant trastuzumab in women with early stage breast cancer, including randomized design, time-to-event endpoints, hazard ratios, confidence intervals, survival methodology,…
- FIDELIO-DKDAn independent statistical analysis of FIDELIO-DKD, the randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and diabetic kidney disease. Includes the primary renal composite, cardiovascular…
- FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
- FINEARTS-HFIndependent statistical analysis of FINEARTS-HF, the randomized phase 3 trial evaluating finerenone versus placebo in participants with heart failure and left ventricular ejection fraction greater than or equal to 40%.
- FIRSTANAIndependent statistical analysis of the randomized phase 3 FIRSTANA trial of cabazitaxel versus docetaxel, both with prednisone, in patients with metastatic castration-resistant prostate cancer.
- FLAMEIndependent statistical analysis of the FLAME phase 3 trial of QVA149 versus LABA/ICS in COPD, including exacerbation rates, time-to-event analyses, non-inferiority methodology, safety, and statistical interpretation.
- FLAURAComplete statistical analysis of the phase 3 FLAURA trial of osimertinib versus standard-of-care EGFR-TKI therapy in locally advanced or metastatic EGFR sensitising mutation-positive non-small cell lung cancer.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FREEDOM-C2Independent statistical analysis of the FREEDOM-C2 phase 3 trial of UT-15C SR versus placebo for pulmonary arterial hypertension, including the 6-minute walk distance endpoint, non-parametric ANCOVA, secondary analyses, safety, and statistical interpretation.
- FREEDOM-MIndependent statistical analysis of FREEDOM-M, a randomized phase 3 trial of oral treprostinil versus placebo for pulmonary arterial hypertension, including 6-minute walk distance, statistical methodology, secondary analyses, safety, and interpretation.
- FRESCO-2Independent statistical analysis of the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care versus placebo plus best supportive care in metastatic colorectal cancer, including overall survival, progression-free survival, response, statistical…
- GADOLINIndependent statistical analysis of the phase 3 GADOLIN trial of obinutuzumab plus bendamustine versus bendamustine alone in participants with rituximab-refractory, indolent non-Hodgkin's lymphoma.
- GALACTIC-HFIndependent statistical analysis of GALACTIC-HF, the randomized phase 3 trial of omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, including time-to-event methods, KCCQ analysis, confidence intervals, multiplicity, and safety.
- GALILEOComplete statistical analysis of the GALILEO phase 3 trial comparing a rivaroxaban-based antithrombotic strategy with an antiplatelet-based strategy after transcatheter aortic valve replacement, including endpoints, hazard ratios, confidence intervals, non-inferiority analysis, safety,…
- GOG-0252Independent statistical analysis of GOG-0252, a randomized phase 3 trial of bevacizumab with intravenous or intraperitoneal chemotherapy in patients with stage II-III ovarian epithelial, fallopian tube, or primary peritoneal cancer.
- GOLDEN-3Independent statistical analysis of GOLDEN-3 (NCT02347761), a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its FEV1 endpoint, MMRM methodology, multiplicity control, confidence intervals, and reported results.
- GOLDEN-4Independent statistical analysis of GOLDEN-4, a randomized phase 3 trial of nebulized SUN-101 in patients with COPD, including its MMRM methodology, primary FEV1 results, multiplicity approach, safety data, and statistical interpretation.